Acadia Pharmaceuticals Inc’s recently made public that its PRINCIPAL ACCOUNTING OFFICER Kihara James unloaded Company’s shares for reported $9481.0 on Feb 24 ’25. In the deal valued at $19.96 per share,475 shares were sold. As a result of this transaction, Kihara James now holds 20,228 shares worth roughly $0.37 million.
Then, Schneyer Mark C. sold 773 shares, generating $15,429 in total proceeds. Upon selling the shares at $19.96, the EVP, CHIEF FINANCIAL OFFICER now owns 53,882 shares.
Before that, Teehan Brendan sold 10,329 shares. Acadia Pharmaceuticals Inc shares valued at $173,630 were divested by the EVP, COO, HEAD OF COMMERCIAL at a price of $16.81 per share. As a result of the transaction, Teehan Brendan now holds 62,105 shares, worth roughly $1.13 million.
Deutsche Bank initiated its Acadia Pharmaceuticals Inc [ACAD] rating to a Hold in a research note published on February 11, 2025; the price target was $22. A number of analysts have revised their coverage, including Guggenheim’s analysts, who decreased its forecast for the stock in early January from “a Buy” to “a Neutral”. Morgan Stanley revised its rating on August 07, 2024. It rated ACAD as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of ACAD
On Monday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock fall -7.35% to $18.16. Over the last five days, the stock has lost -6.78%. Acadia Pharmaceuticals Inc shares have fallen nearly -1.04% since the year began. Nevertheless, the stocks have fallen -23.52% over the past one year. While a 52-week high of $24.53 was reached on 02/21/25, a 52-week low of $14.15 was recorded on 01/14/25. SMA at 50 days reached $18.33, while 200 days put it at $16.66.
Levels Of Support And Resistance For ACAD Stock
The 24-hour chart illustrates a support level at 17.61, which if violated will result in even more drops to 17.06. On the upside, there is a resistance level at 19.20. A further resistance level may holdings at 20.24. The Relative Strength Index (RSI) on the 14-day chart is 43.03, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.37, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.67%. Stochastics %K at 36.05% indicates the stock is a holding.
The most recent change occurred on June 27, 2024 when BMO Capital Markets began covering the stock and recommended ‘”an Outperform”‘ rating along with a $31 price target.
